FVFrans C. Visser

Frans C. Visser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Frans C. Visser has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • FDG PET as a predictor of response to resynchronisation therapy in patients with ischaemic cardiomyopathy

    by C. M. C. van Campen, Frans C. Visser, Arno P. van der Weerdt, Paul Knaapen, Emile F. I. Comans, Adriaan A. Lammertsma, Carel C. de Cock, Cees A. Visser

    Purpose Although resynchronisation therapy (CRT) is a promising addition to heart failure therapy, a substantial number of patients do not respond to CRT. As FDG PET has routinely been used for prediction of improvement after revascularisation in ischaemic cardiomyopathy, it was hypothesised that there is also a relationship between the extent of viable tissue and improvement as a result of CRT. Methods Thirty-nine patients with ischaemic cardiomyopathy (ejection fraction 27 ± 9%) and a wide QRS complex underwent temporary pacing to determine the optimal pacing combination, i.e. that with the highest increase in cardiac index (CI) compared with baseline (measured by Doppler echocardiography). All patients also underwent FDG PET imaging. In 19 patients, CI measurements were repeated 10–12 weeks after permanent biventricular pacemaker implantation. Results Echocardiography (13-segment model) showed a mean of 9.8 ± 1.6 dyssynergic segments, with preserved FDG uptake in 4.1 ± 2.4 segments. CI improvement at the optimal pacing site was 20 ± 9%. There was a linear relationship between the extent of viable tissue and CI improvement during pacing (p < 0.001). Using a cut-off value of more than three viable segments (ROC analysis), FDG PET had a sensitivity of 72% and a specificity of 71% for detection of the presence of haemodynamic improvement (i.e. a CI improvement >15%). The relation between CI improvement and viable tissue was similar at follow-up. Conclusion A correlation was found between the extent of viable tissue and the haemodynamic response to CRT in patients with ischaemic cardiomyopathy, suggesting that FDG PET imaging may be useful to discriminate between responders and non-responders to CRT.


  • Comparison of the haemodynamics of different pacing sites in patients undergoing resynchronisation treatment: need for individualisation of lead localisation

    by C M C van Campen, F C Visser, C C de Cock, H S Vos, O Kamp, C A Visser

    Background: Biventricular pacing is a new therapy for the treatment of heart failure. However, a substantial number of patients do not respond to this therapy. Hypothesis: Individually determined maximal pacing sites will improve the haemodynamic response and increase the number of responders. Methods: In 48 patients with heart failure, the acute haemodynamic effects of nine different pacing configurations were studied, using two right and left ventricular pacing sites and their combinations. Cardiac index was measured using Doppler echocardiography. For further analysis, the combination with the highest cardiac index improvement was compared with baseline. Moreover, the number of responders was calculated using a cut-off value of 10% increase in cardiac index. Results: The mean (SD) increase in cardiac index ranged between 3.8% (6.0%) and 11.1% (8.6%). The pacing site with maximal cardiac index was highly variable between patients, and here the cardiac index increased to 14.8% (7.6%; (pConclusion: Individualisation of pacing configuration for biventricular pacing leads to further haemodynamic improvement in patients with heart failure and reduces the number of patients not responding to this therapy.


  • Open Access

    Early and long-term outcome of elective stenting of the infarct-related artery in patients with viability in the infarct-area: Rationale and design of the Viability-guided Angioplasty after acute Myocardial Infarction-trial (The VIAMI-trial)

    by Ramon B van Loon, Gerrit Veen, Otto Kamp, Jean Gf Bronzwaer, Cees A Visser, Frans C Visser

    Background: Although percutaneous coronary intervention (PCI) is becoming the standard therapy in ST-segment elevation myocardial infarction (STEMI), to date most patients, even in developed countries, are reperfused with intravenous thrombolysis or do not receive a reperfusion therapy at all. In the post-lysis period these patients are at high risk for recurrent ischemic events. Early identification of these patients is mandatory as this subgroup could possibly benefit from an angioplasty of the infarct-related artery. Since viability seems to be related to ischemic adverse events, we initiated a clinical trial to investigate the benefits of PCI with stenting of the infarct-related artery in patients with viability detected early after acute myocardial infarction. Methods: The VIAMI-study is designed as a prospective, multicenter, randomized, controlled clinical trial. Patients who are hospitalized with an acute myocardial infarction and who did not have primary or rescue PCI, undergo viability testing by low-dose dobutamine echocardiography (LDDE) within 3 days of admission. Consequently, patients with demonstrated viability are randomized to an invasive or conservative strategy. In the invasive strategy patients undergo coronary angiography with the intention to perform PCI with stenting of the infarct-related coronary artery and concomitant use of abciximab. In the conservative group an ischemia-guided approach is adopted (standard optimal care). The primary end point is the composite of death from any cause, reinfarction and unstable angina during a follow-up period of three years. Conclusion: The primary objective of the VIAMI-trial is to demonstrate that angioplasty of the infarct-related coronary artery with stenting and concomitant use of abciximab results in a clinically important risk reduction of future cardiac events in patients with viability in the infarct-area, detected early after myocardial infarction.


  • Open Access

    Admission Blood Glucose Level as Risk Indicator of Death After Myocardial Infarction in Patients With and Without Diabetes Mellitus

    by Ischa Stranders, Michaela Diamant, Rogier E. van Gelder, Hugo J. Spruijt, Jos W. R. Twisk, Robert J. Heine, Frans C. Visser

    Diabetes mellitus is associated with a high risk of coronary heart disease,1,2 and subjects with diabetes have a substantially increased risk of death after acute myocardial infarction (AMI), as compared with nondiabetic age-matched controls.3,4 High blood glucose levels in patients admitted with AMI are common and are associated with an increased risk of death in both diabetic5-7 and nondiabetic7-10 subjects. A recent report showed that, of patients who had no known diabetes at the time of AMI and whose admission blood glucose levels were less than 200 mg/dL (11.1 mmol/L), up to 40% were diagnosed as having impaired glucose tolerance and 25% as having diabetes when tested 3 months after discharge.11 The high prevalence of undiscovered abnormal glucose metabolism among patients with AMI, compatible with the prediabetic state as well as frank diabetes, may in part explain the association between admission glucose levels and mortality, especially in subjects who are not diagnosed as having diabetes at the time of the AMI.9,10 Although the diagnosis of diabetes may not be made on the basis of a single blood glucose value,12,13 casual blood glucose levels of 200 mg/dL (11.1 mmol/L) or more suggest the existence of diabetes, and as a consequence, the risk of mortality after AMI in this group may be disproportionately high and should be evaluated separately. In the study by Norhammar et al,11 subjects with glucose levels of 200 mg/dL (11.1 mmol/L) or higher were excluded.